𝔖 Bobbio Scriptorium

✦ LIBER ✦

Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial

✍ Scribed by Adele M.Kaplan Gilpin; Janet T Holbrook; Douglas A Jabs; Curtis L Meinert

Book ID: 114186973
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 123 KB
Volume: 24
Category: Article
ISSN: 0197-2456
DOI: 10.1016/s0197-2456(02)00268-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A systematic review of the reporting of

A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials

✍ Ricardo M Fernandes; Johanna H van der Lee; Martin Offringa 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 452 KB

Safety results from a pooled analysis of

Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

✍ Langley, R.G.; Papp, K.; Gottlieb, A.B.; Krueger, G.G.; Gordon, K. B.; Williams, 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB

Efficacy and safety results of secukinum

Efficacy and safety results of secukinumab, a fully human monoclonal anti-interleukin-17a antibody, in the treatment of moderate-to-severe plaque psoriasis: A phase II regimen-finding trial

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Retreatment efficacy and long-term safet

Retreatment efficacy and long-term safety of the fully human, interleukin -12/-23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Ustekinumab, an anti-IL-12/23 p40 monocl

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

✍ Kavanaugh, Arthur (author);Ritchlin, Christopher (author);Rahman, Proton (author 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 984 KB

Ustekinumab, an anti-IL-12/23 p40 monocl

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials

✍ Kavanaugh, Arthur (author);Ritchlin, Christopher (author);Rahman, Proton (author 📂 Article 📅 2014 🏛 BMJ Publishing Group 🌐 English ⚖ 984 KB